Canada’s Drug Agency | Drugs, Health Technologies and Systems.

durvalumab

Details

Generic Name:
durvalumab
Project Status:
Pending
Therapeutic Area:
Muscle invasive bladder cancer
Manufacturer:
AstraZeneca Canada
Call for patient/clinician input open:
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0414-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Imfinzi in combination with cisplatin-based chemotherapy as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy, is indicated for the treatment of patients with muscle invasive bladder cancer (MIBC).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Imfinzi in combination with cisplatin-based chemotherapy as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy, is indicated for the treatment of patients with muscle invasive bladder cancer (MIBC).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : May 7, 2025